Detecting Heart Disease Using First Pass Imaging With Gated SPECT Perfusion
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01137409|
Recruitment Status : Completed
First Posted : June 4, 2010
Last Update Posted : May 20, 2015
|Condition or disease|
|Ischemic Heart Disease|
Show Detailed Description
|Study Type :||Observational|
|Actual Enrollment :||40 participants|
|Official Title:||Detecting Heart Disease Using First Pass Imaging With Gated SPECT Perfusion|
|Study Start Date :||August 2010|
|Actual Primary Completion Date :||December 2014|
Suspected or Diagnosed with Coronary artery disease
All patients with suspected or previously diagnosed coronary artery disease
- To determine if stress first pass imaging in conjunction with gated SPECT, with or with out low level exercise,will improve the sensitivity for detecting ischemic heart disease [ Time Frame: First pass imaging done in conjunction with SPECT study ]First pass imaging will be done in conjunction with the clinically indicated SPECT study.
- To determine if first pass imaging provides a more reproducible approach for evaluation of both rest and stress global LV function over gated SPECT perfusion imaging compared with 3D echocardiography [ Time Frame: Immediately following administration of regadenoson. ]Echocardiography will be done immediately following the administration of regadenoson.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01137409
|United States, Connecticut|
|Yale New Haven Hospital|
|New Haven, Connecticut, United States, 06510|
|Principal Investigator:||Albert Sinusas, MD||Yale University|